Kemin Pharma establishes new offices in India

The new facility enables Kemin Pharma to expand its R&D activities in India, as the organization advances its pipeline of human therapeutic products through clinical development and the launch of its lead product, the Bacillus subtilis probiotic PB6 into global markets.

The office will initially staff up to 20 clinical research and general management personnel, with research facilities at the same location as well as in Gummidpundi, Chennai, India.

Keith Bostian, president of Kemin Pharma, said: “We have been operating in India over the past year primarily in early clinical research. We are now well poised to increase our team and capabilities in India as an integral component of our global R&D effort.

“Our plans in India are to move toward earlier preclinical development and discovery stages of the pharmaceutical research process, aiming to become a lead company in the rapidly growing Indian pharmaceutical industry.”